Emergent Biosolutions’ (EBS) Buy Rating Reaffirmed at HC Wainwright

Emergent Biosolutions (NYSE:EBS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 66.53% from the company’s current price.

A number of other equities analysts also recently commented on the company. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. JPMorgan Chase & Co. started coverage on shares of Emergent Biosolutions in a research report on Friday, August 21st. They issued an “underweight” rating for the company. Weiss Ratings raised Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Zacks Research raised Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Finally, UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Emergent Biosolutions currently has an average rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Trading Down 3.3%

EBS stock opened at $6.00 on Wednesday. The business’s 50-day moving average is $6.60 and its 200 day moving average is $7.83. The stock has a market cap of $307.88 million, a price-to-earnings ratio of -1.69 and a beta of 2.34. The company has a current ratio of 5.42, a quick ratio of 2.95 and a debt-to-equity ratio of 1.70. Emergent Biosolutions has a 12-month low of $4.36 and a 12-month high of $14.06.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The business had revenue of $234.30 million during the quarter, compared to analysts’ expectations of $177.50 million. On average, sell-side analysts anticipate that Emergent Biosolutions will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Paul Williams sold 3,000 shares of Emergent Biosolutions stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the completion of the transaction, the senior vice president directly owned 159,098 shares in the company, valued at approximately $1,336,423.20. This trade represents a 1.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by company insiders.

Institutional Trading of Emergent Biosolutions

Several institutional investors and hedge funds have recently made changes to their positions in EBS. Integrated Wealth Concepts LLC acquired a new stake in shares of Emergent Biosolutions in the second quarter valued at approximately $29,000. Legal & General Group Plc bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth $31,000. Public Employees Retirement System of Ohio purchased a new position in Emergent Biosolutions during the 2nd quarter worth approximately $36,000. CANADA LIFE ASSURANCE Co acquired a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $45,000. Finally, California State Teachers Retirement System boosted its stake in Emergent Biosolutions by 112.8% during the 2nd quarter. California State Teachers Retirement System now owns 6,008 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 3,185 shares during the period. 78.40% of the stock is owned by hedge funds and other institutional investors.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.